透雲生物(01332.HK)向梧桐國際(00613.HK)出售投資控股公司90.1%股權
透雲生物(01332.HK)公佈,於上星期四(10月29日)訂立協議,同意以4,000萬元,向梧桐國際(00613.HK)附屬出售一間從事投資控股及買賣香港上市證券的公司90.1%股權。
公司預期,完成後確認虧損約577.1萬元,今年9月底公司應佔出售公司資產淨值4,577.1萬元減代價4,000萬元。公司應佔虧損預期約爲352萬元。
於完成後,出售公司將不再爲公司的非全資附屬公司,而其相關財務表現、資產及負債於出售事項後將不會於集團的綜合財務報表入賬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.